Site Map

v  Home

v  About Us
   - Company Profile
   - Milestones
   - Mission
   - Quality Policy
   - Human resource
   - e - Bulletin of Natco Pharma
   - Natco IPR Policy

v  Products
   - Dosage Forms
   - Bulk Activates and Intermediates
   - New

v  Research

v  Operations
   - Formulation
   - Parenterals
   - Bulk Drugs
        > Pollution Management
        > Employees Management
        > Special Environment Efforts
   - R&D

v  Finance

v  Marketing
   - Domestic
        > Domestic Generic & Branded Formulations
        > Domestic Bulk Drugs
        > Contract Manufacturing
        > Marketing Networks
   - International
        > Export Generic Formulations
        > Export Bulk Drugs
        > Export Horizon

v  NATCO Trust

v  Sitemap

v  Contact Us

 
NATCO confirms filing of ANDA for Generic Revlimid 31/08/2010
NATCO denies speculative news 23/08/2010
NATCO reports increased earnings and profits 31/07/2010
NATCO launches Anastrazole in the USA 29/06/2010
NATCO records higher sales, profits 25/06/2010
NATCO launches BENDIT 07/04/2010
NATCO declares an interim dividend of Rs. 2 per share 27/01/2010
Press Release 09/01/2010
NATCO records increase in revenues, profits 29/10/2009
Natco’s note on anti-cancer drug Albupax 19/10/2009
NATCO Pharma launches Swine Flu medicine 18/09/2009
NATCO’s partner – Mylan’s – ANDA accepted for review of Glatiramer Acetate 14/09/2009
News | Careers | Privacy Policy
NATCO House, Road No: 2, Banjara Hills, Hyderabad - 500 033
Powered by www.sholay.in